Factor XIII, also known as fibrin stimulating factor is a Zymogen found in he blood of humans along with some other animals. It is activated by Thrombin to Factor XIIIa which enables it to preform it's enzymatic functions of cross-linking fibrin as part of the coagulation cascade. It was first detected in 1944 by Robbins. Factor XIII is a heterotetramer that consists of 2 enzymatic A peptides and 2 non-enzymatic B peptides.
Function
Factor XIII is a transglutaminase that circulates throughout the blood as a heterotetramer. The B subunits bind to the clot structure. When fibrin is present, thrombin cleaves the R37-G38 peptide bond in the A subunit that reveals it's active enzymatic region at the N-terminus. Calcium ions further activate the A subunits through a change in shape. The calcium ions additionally dissociate the non-covalently bound B subunits. The remaining dimer of two active A subunits, FactorXIIIa, crosslinks fibrin by forming isopeptide bonds between glutamines and lysines within the fibrin. The crosslinks make the clot more durable and more resistant to fibrinolysis due to premature enzymatic degradation. It additionally has been found to play a role in proper wound healing, carrying pregnancy to full term, and in the development of new blood vessels.
Structural highlights
The fibrin stabilization factor is a heterotetramer that circulates throughout the blood plasma as a 320 kda molecule. It consists of a dimer of A subunits and a dimer of B subunits. The FXIIIA subunit is composed of 4 structural units: Beta sandwich, core, barrel-1, and barrel-2 domains. The A subunit has a 37 amino acid N-terminal activation peptide, this is cleaved by thrombin during FXIII activation to FXIIIa.
FXIIIB subunit is made up of ten Sushi domains which are each composed of approximately 60 amino acids. The B subunit is known to have a protective role, but recent research has suggested that there may be a regulatory role as well.
Disease
Factor XIII deficiency is a genetic bleeding disorder. It is an autosomal recessive disease. It is rare with Iran having the leading number of cases in the world. Individuals with this disorder form clots normally, however the clots are unstable and typically degrade which results in long bleeding episodes. Most phenotypical changes in factor XIII deficiency are caused by mutations in the A subunits.
The symptoms of Factor XIII deficiency vary but in 80% of cases appear after birth with a bleeding episode stemming from the umbilical stump. Bleeding can occur spontaneously or from various activities. Commonly associated symptoms include chronic nosebleeds, bleeding from the gums, discoloration of the skin, and hematomas. These individuals typically bruise easily and spontaneously. 30% of people experience spontaneous intracranial hemorrhages. In homozygous woman spontaneous recurrent miscarriages can occur.
Relevance
